News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
483,278 Results
Type
Article (8059)
Company Profile (139)
Press Release (475175)
Multimedia
Podcasts (4)
Webinars (7)
Section
Business (166799)
Career Advice (312)
Deals (25739)
Drug Delivery (7)
Drug Development (52878)
Employer Resources (15)
FDA (9761)
Job Trends (8578)
News (238260)
Policy (17900)
Tag
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (484)
Accelerated approval (21)
ADA (18)
Adcomms (1)
Allergies (94)
Alliances (33161)
ALS (102)
Alzheimer's disease (966)
Antibody-drug conjugate (ADC) (254)
Approvals (10339)
Artificial intelligence (310)
ASCO (159)
Autoimmune disease (197)
Automation (29)
Bankruptcy (262)
Best Places to Work (6961)
BIO (36)
BIOSECURE Act (1)
Biosimilars (104)
Biotechnology (88)
Bladder cancer (132)
Brain cancer (28)
Breast cancer (501)
Cancer (3565)
Cardiovascular disease (213)
Career advice (253)
Career pathing (1)
CAR-T (169)
Celiac Disease (1)
Cell therapy (469)
Cervical cancer (34)
Clinical research (47740)
Collaboration (1207)
Commercialization (1)
Compensation (1390)
Complete response letters (33)
COVID-19 (750)
CRISPR (62)
C-suite (708)
Cystic fibrosis (84)
Data (5508)
Denatured (4)
Depression (101)
Dermatology (59)
Diabetes (336)
Diagnostics (4152)
Digital health (36)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (145)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (158)
Earnings (73052)
Editorial (1)
Employer branding (2)
Employer resources (15)
Events (87454)
Executive appointments (681)
FDA (12290)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (17)
Frontotemporal dementia (23)
Funding (894)
Gene editing (123)
Generative AI (9)
Gene therapy (309)
GLP-1 (284)
Government (940)
Grass and pollen (2)
Guidances (280)
Healthcare (9322)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (60)
Immunology and inflammation (96)
Immuno-oncology (54)
Indications (151)
Infectious disease (936)
Inflammatory bowel disease (125)
Inflation Reduction Act (4)
Influenza (83)
Intellectual property (247)
Interviews (43)
IPO (12378)
IRA (2)
Job creations (1970)
Job search strategy (242)
JPM (1)
Kidney cancer (16)
Labor market (1)
Layoffs (60)
Legal (5196)
Liver cancer (43)
Longevity (15)
Lung cancer (490)
Lymphoma (242)
Machine learning (27)
Management (3)
Manufacturing (511)
Marketing (7)
MASH (116)
Medical device (8634)
Medtech (8758)
Mergers & acquisitions (14352)
Metabolic disorders (690)
mRNA (50)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (213)
Neuropsychiatric disorders (38)
Neuroscience (1786)
NextGen: Class of 2026 (3157)
Non-profit (844)
Obesity (219)
Opinion (11)
Ovarian cancer (156)
Pain (169)
Pancreatic cancer (191)
Parkinson's disease (196)
Partnered (11)
Patents (457)
Patient recruitment (477)
Peanut (31)
People (41162)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15430)
Phase 2 (21317)
Phase 3 (14354)
Pipeline (6662)
Policy (19)
Postmarket research (1570)
Preclinical (6527)
Press Release (34)
Prostate cancer (187)
Psychedelics (7)
Radiopharmaceuticals (187)
Rare diseases (557)
Real estate (3022)
Recruiting (6)
Regulatory (14682)
Reports (16)
Research institute (582)
Resumes & cover letters (48)
Rett syndrome (39)
RNA editing (5)
RSV (47)
Schizophrenia (98)
Series A (149)
Series B (117)
Service/supplier (4)
Sickle cell disease (62)
Spinal muscular atrophy (87)
Sponsored (6)
Startups (2019)
Stomach cancer (3)
Supply chain (49)
Vaccines (311)
Venture capital (17)
Weight loss (70)
Women's health (75)
Date
Last 7 days (261)
Last 30 days (1076)
Last 365 days (19037)
2026 (10762)
2025 (19255)
2024 (22992)
2023 (26554)
2022 (34600)
2021 (37183)
2020 (33481)
2019 (23281)
2018 (17479)
2017 (18773)
2016 (17928)
2015 (24267)
2014 (21689)
2013 (18142)
2012 (20227)
2011 (20446)
2010 (20335)
Location
Africa (234)
Alabama (71)
Alaska (2)
Arizona (292)
Arkansas (11)
Asia (17858)
Australia (2098)
California (11523)
Canada (3043)
China (505)
Colorado (464)
Connecticut (390)
Delaware (203)
Europe (24609)
Florida (1716)
Georgia (364)
Hawaii (2)
Idaho (46)
Illinois (679)
India (42)
Indiana (308)
Iowa (13)
Japan (386)
Kansas (98)
Kentucky (30)
Louisiana (24)
Maine (25)
Maryland (1154)
Massachusetts (7587)
Michigan (299)
Minnesota (539)
Mississippi (4)
Missouri (78)
Montana (20)
Nebraska (11)
Nevada (112)
New Hampshire (60)
New Jersey (2536)
New Mexico (12)
New York (2736)
North Carolina (1228)
North Dakota (4)
Northern California (5735)
Ohio (268)
Oklahoma (14)
Oregon (14)
Pennsylvania (2192)
Puerto Rico (20)
Rhode Island (30)
South America (414)
South Carolina (75)
South Dakota (1)
Southern California (4780)
Tennessee (113)
Texas (1858)
United States (37497)
Utah (345)
Vermont (1)
Virginia (146)
Washington D.C. (38)
Washington State (893)
West Virginia (1)
Wisconsin (73)
483,278 Results for "fluent inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Fluent BioSciences Debuts PIPseq™ V with Unique Molecular Counting Strategy
Fluent BioSciences, a leader in single-cell technology innovation, is proud to herald the launch of our latest product line, the PIPseq V 3' Single Cell RNA Sequencing Kits.
May 29, 2024
·
1 min read
Biotech Beach
Breaking Barriers: Fluent BioSciences and Element Biosciences Collaborate to Enhance scRNA-seq Access
Fluent BioSciences, a leader in breakthrough single-cell analysis technology, and Element Biosciences, a pioneer in novel sequencing solutions, are excited to announce their collaboration to enhance the accessibility and scalability of single-cell RNA sequencing.
December 19, 2023
·
2 min read
Genetown
Pioneering Scalable Single Cell RNA Sequencing: A Partnership Announced with Fluent BioSciences and Singular Genomics®
Fluent BioSciences is excited to announce a partnership with Singular Genomics, a company leveraging novel next-generation sequencing and multiomics technologies to empower researchers and clinicians.
November 2, 2023
·
2 min read
Genetown
Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits powered by Ultima Genomics sequencing, prototype kits now shipping
Fluent BioSciences is thrilled to announce the award of an NIH Small Business Innovation Research (SBIR) Phase II grant, funded by the National Institute of General Medical Sciences (NIGMS, 2 R44 GM137648).
March 21, 2024
·
3 min read
Genetown
Fluent Biosciences announces early access availability of transformative direct-guide capture for single cell analysis for complex CRISPR screening in Particle-templated Instant Partitions (PIPseq-CRISPR)
Fluent BioSciences, a life sciences company focused on making single-cell analysis simple and accessible to every researcher, announces early access availability of new kits and reagents for direct CRISPR guide capture in particle templated instant partitions (PIPseq-CRISPR).
March 21, 2024
·
1 min read
Genetown
Fluent BioSciences Awarded NIH SBIR Grant to Revolutionize Single Cell Analysis
Fluent BioSciences, a cutting edge life sciences company leading the charge in revolutionizing single cell analysis through simple, cost-effective, and highly scalable single-cell RNA sequencing solutions is thrilled to announce the award of an NIH Small Business Innovation Research Phase II grant, funded by the National Institute of General Medical Sciences.
September 12, 2023
·
2 min read
Genetown
New 5th Generation Chemistry from Fluent BioSciences Eliminates Key Limitations of Single Cell Analysis, Achieving 64% Improved Sensitivity
Fluent BioSciences, a leading life sciences company dedicated to transforming single-cell analysis with innovative, cost-effective, and scalable solutions, announces the launch of the new PIPseq T10 v5.0 Kit.
October 17, 2023
·
1 min read
Business
Fluent BioSciences Partners with Genspace to Unleash the Power of PIPseq™: Empowering Community Scientists to Transform Genomic Research
Fluent BioSciences, a life science tools company, delivering single-cell technology to laboratories across the United States and abroad, collaborates with Genspace by sponsoring a community science workshop in Brooklyn, NY.
May 30, 2023
·
2 min read
Genetown
Fluent BioSciences Releases Comprehensive White Paper Highlighting Increased Performance Metrics with the Latest v4.0 PIPseq Single Cell RNA Sequencing Kits
Fluent BioSciences has published a white paper highlighting the performance improvements of the recently announced v4.0 chemistry as compared to the previous v3.0 chemistry.
May 4, 2023
·
1 min read
Genetown
Fluent BioSciences Partners with GenomeWeb and NYU Grossman School of Medicine’s Liddelow Lab to Host Webinar on Revolutionary PIPseq scRNA-Seq Technology with Upcoming bioRxiv Publication
Fluent BioSciences in collaboration with GenomeWeb and the Liddelow Lab, will host a webinar to explore the use of PIPseq, an innovative single-cell RNA sequencing technology.
May 17, 2023
·
1 min read
1 of 48,328
Next